NCT01651143 - Proof of Biological Activity of SAR100842 in Systemic Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

April 30, 2014

Conditions

Systemic Sclerosis

Interventions

DRUG

SAR100842

"Pharmaceutical form: tablets~Route of administration: oral"

DRUG

Placebo (for SAR100842)

"Pharmaceutical form: tablets~Route of administration: oral"

Trial Locations (13)

Investigational Site Number 756001, Zurich

Investigational Site Number 840008, Pittsburgh

Investigational Site Number 840003, Washington D.C.

Investigational Site Number 380001, Milan

Investigational Site Number 840004, Baltimore

Investigational Site Number 840002, Ann Arbor

Investigational Site Number 250003, Lille

Investigational Site Number 250001, Paris

Investigational Site Number 840006, Scottsdale

Investigational Site Number 840001, Boston

Investigational Site Number 840007, New Brunswick

Investigational Site Number 826001, London

Investigational Site Number 826002, Salford